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INTRODUCTION
Organic cation/carnitine transporter (OCTN) of the solute 
carrier (SLC) 22 family has two isoforms in humans, OCTN1 and 
OCTN2 [1]. OCTN1, which is encoded by SLC22A4, is expressed 
in various organs, including the bone marrow, gut, heart, 
kidney, and lung [1]. OCTN1 transports various endogenous 
substances or drugs, including ergothioneine, carnitine, tetra-
ethylammonium, and gabapentin, in a sodium- or pH-dependent 
manner according to the features of the substrates [1-5]. Although 
the physiological role of OCTN1 is not yet well established, 
previous studies have suggested that this transporter accumulates 
the anti-oxidant ergothioneine for protecting the body against 
oxidative stress [1,5]. 
Few studies have investigated the role of the genetic variants of 
OCTN1 in the expression or transport activity of this transporter. 
Toh et al. [6] identified four single nucleotide polymorphisms 
(SNPs) of OCTN1 that impair transport activity. In addition, 
Tahara et al. [7] investigated the functions and effects of SNPs in 
the proximal promoter region of OCTN1, and determined that all 
OCTN1 haplotypes identified in their study population showed 
promoter activity comparable to that of the reference. Previously, 
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ABSTRACT Crohn’s disease (CD) is a chronic inflammatory bowel disease with 
multifactorial causes including environmental and genetic factors. Several studies 
have demonstrated that the organic cation/carnitine transporter 1 (OCTN1) non-
synonymous variant L503F is associated with susceptibility to CD. However, it was 
reported that L503F is absent in Asian populations. Previously, we identified and 
functionally characterized genetic variants of the OCTN1 promoter region in Koreans. 
In that study, four variants demonstrated significant changes in promoter activity. 
In the present study, we determined whether four functional variants of the OCTN1 
promoter play a role in the susceptibility to or clinical course of CD in Koreans. 
To examine it, the frequencies of the four variants of the OCTN1 promoter were 
determined by genotyping using DNA samples from 194 patients with CD and 287 
healthy controls. Then, associations between genetic variants and the susceptibility 
to CD or clinical course of CD were evaluated. We found that susceptibility to CD was 
not associated with OCTN1 functional promoter variants or haplotypes showing 
altered promoter activities in in vitro assays. However, OCTN1 functional promoter 
haplotypes showing decreased promoter activities were significantly associated 
with a penetrating behavior in CD patients (HR=2.428, p=0.009). Our results suggest 
that the OCTN1 functional promoter haplotypes can influence the CD phenotype, 
although these might not be associated with susceptibility to this disease. 
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Table 1. Comparison of the frequency of OCTN1 variants between 
patients with CD and controls 
Variant Patient, n (%) Control, n (%) p value
g.–1875T>A +/+ 110 (56.7) 158 (55.1) 0.753
   (0.721)+/– 74 (38.1) 116 (40.4)
–/– 10 (5.2) 13 (4.5)
g.–1745A>G +/+ 96 (49.5) 134 (46.7) 0.259
   (0.547)+/– 75 (38.7) 128 (44.6)
–/– 23 (11.9) 25 (8.7)
g.–1145A>G +/+ 30 (15.5) 37 (12.9) 0.394
   (0.424)+/– 78 (40.2) 134 (46.7)
–/– 86 (44.3) 116 (40.4)
g.–248C>G +/+ 30 (15.5) 36 (12.5) 0.438
   (0.361)+/– 78 (40.2) 134 (46.7)
–/– 86 (44.3) 117 (40.8)
The p values were obtained using a recessive (+/+ or +/- vs. -/-) 
model. The p values in parenthesis were obtained from analyses 
using the dominant (+/+ vs. +/- or -/-) model. 
we identified and functionally characterized novel OCTN1 
promoter variants in Koreans [8]. In that study, we observed that 
four promoter SNPs resulted in significantly altered promoter 
activity, compared to the reference. Two of them, g.–1875T>A and 
g.–1745A>G, demonstrated increased promoter activity, whereas 
the other two, g.–1145A>G and g.–248C>G, demonstrated 
decreased promoter activity. Very few studies have investigated 
the effect of OCTN1 genetic variants on the response or 
pharmacokinetics of drugs. Urban et al. [2] reported that OCTN1 
genetic variants could impact the pharmacokinetics of the anti-
epilepsy drug, gabapentin. They found that a non-synonymous 
variant of OCTN1, L503F demonstrated decreased transport 
activity for gabapentin, and subjects who were homozygous for 
this variant demonstrated significantly decreased renal secretion 
of gabapentin. 
Crohn’s disease (CD) is a chronic idiopathic inflammatory 
bowel disease that could involve the whole gastrointestinal tract. 
Although the pathogenesis of CD remains unclear, it is accepted 
that CD can be induced by abnormal immune responses against 
gut flora, in particular, in genetically susceptible individuals [9]. 
To date, a large number of studies have examined the association 
between genetic variants and susceptibility to or clinical 
phenotypes of CD, and many genes, such as NOD2, ATG16L1, 
IRGM, IBD5, and TNFSF15 were shown to be significantly 
associated with CD [10-13]. In the case of OCTN, Peltekova et al. 
[4] reported an association between the TC haplotype of OCTNs 
consisting of two genetic variants, OCTN1, L503F and OCTN2, 
g.–207G>C and susceptibility to CD. This finding was validated 
by several other association studies [14-22]. However, previous 
studies reported that these two variants are not found in Asian 
populations [17-19]. In particular, to our knowledge, no other 
study has investigated the association between genetic variants in 
the OCTN1 promoter as well as susceptibility to CD. Therefore, 
in the present study, we investigated whether the genetic variants 
of the OCTN1 promoter that demonstrated altered promoter 
activity in our previous study could affect the susceptibility to or 
clinical course of CD in Koreans.  
mEThODS
Subjects 
The study protocol was reviewed and approved by the 
Institutional Review Board of the Ewha Medical Center, Seoul, 
Korea, and the Institutional Review Board of Severance Hospital 
at Yonsei University Health System, Seoul, Korea. After receiving 
written informed consent, DNA samples were obtained from 
194 Korean patients with CD. Those diagnosed with CD had at 
least a 24-month follow-up period with assessment by internal 
medicine specialists. The CD patients were subgrouped according 
to age of onset, location, and disease behavior using the Montreal 
Classification [23]. Among disease behaviors, “penetrating 
behavior” refers to the presence of intestinal perforation, intra-
abdominal fistula, or inflammatory mass and/or abscess. For the 
control group, DNA samples were collected from 287 unrelated 
healthy Koreans who had no evidence of abnormalities during 
routine gastrointestinal examinations, showed no gastrointestinal 
symptoms and took no regular medications at Severance 
Hospital. Clinical data were obtained by reviewing the medical 
records.
Genetic analysis of OCTN1 
In the present study, four OCTN1 promoter variants, g.–1875T>A, 
g.–1745A>G, g.–1145A>g, and g.–248C>G, which showed signifi-
cant changes in promoter activity in our previous study [8], 
were genotyped by a SNaPshot assay using an automated DNA 
analyzer (DNA Link, Inc., Seoul, Korea). 
Statistical analysis
To compare the frequency of OCTN1 genetic variations or 
haplotypes between patients and control groups, a χ2-test was 
conducted. Comparisons of the characteristics between patient 
groups according to OCTN1 functional haplotypes were analyzed 
using the χ2-test and t-test. The effects of the OCTN1 functional 
haplotypes on the clinical course (disease behavior, azathioprine 
or anti-TNF agent use, and surgery) of CD were initially 
investigated using the Kaplan-Meier estimator and log-rank 
test to consider time to clinical events. Then, the multivariate 
Cox proportional hazards regression analysis (for each clinical 
parameter) was performed with adjustment for sex and age of 
onset.  
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RESULTS
Association between OCTN1 genotypes or 
haplotypes and susceptibility to CD
We compared the frequencies of OCTN1 functional variants 
or haplotypes reported in our previous study [8] between patients 
with CD and healthy control groups. Table 1 shows the frequency 
of the four variants between the two groups. We observed that 
there was no significant difference in the frequency of any of 
the genetic variants analyzed between the two groups. Using 
genotype data, haplotypes were assembled using the Haploview 
program (version 4.3, Broad Institute, Cambridge, MA, USA). 
There were six promoter haplotypes in our population. The 
frequency of each haplotype in CD patient and control groups is 
listed in Table 2. We observed that the frequency of haplotypes 
in CD patients was comparable with those of the control group. 
These findings indicate that the susceptibility to CD might not be 
affected by OCTN1 functional variants or haplotypes in Koreans.
Effect of the OCTN1 functional promoter haplotype 
on the clinical characteristics of patients with CD
Next, we examined whether the functional promoter 
haplotypes of OCTN1 could affect the clinical characteristics 
of patients with CD, although we found that these haplotypes 
did not affect susceptibility to CD. Here, we hypothesized that 
the OCTN1 functional haplotypes that demonstrated decreased 
promoter activity could be associated with a severe clinical course 
of CD, as the well-known OCTN1 variant L503F demonstrated 
a reduction in transport activity in a previous study [4]. In our 
population, five OCTN1 promoter haplotypes, (H2 to H6) 
were predicted to have decreased promoter activity according 
to the results of our previous study [8]. Therefore, we divided 
the 194 patients into two groups according to the five OCTN1 
haplotypes: a variant group (n=86) and a control group (n=108). 
The variant group consisted of subjects having two of five 
promoter haplotypes, and the control group consisted of subjects 
who were not members of the variant group. First, we compared 
the demographic or clinical characteristics of CD patients and 
observed that the functional haplotypes showing decreased 
OCTN1 promoter activity were not associated with sex, age of 
Table 2. Comparison of the frequency of OCTN1 haplotypes between patients with CD and controls 
ID g.–1875T>A g.–1745A>G g.–1145A>G g.–248C>G Patient, n (%) Control, n (%) p value
H1 T A A C 138 (35.6) 206 (35.9) 0.919
H2 T G G G 120 (30.9) 178 (31.0) 0.979
H3 A A G G 93 (24) 142 (24.7) 0.786
H4 T A G G 36 (9.3) 46 (8.0) 0.492
H5 T A A G 0 (0) 2 (0.3) 0.245
H6 A G G G 1 (0.3) 0 (0) 0.250
The SNPs were marked in bold-faced letters.
The minor alleles were underlined. 
Table 3. Demographic and clinical characteristics of patients according to OCTN1 haplotypes 
Parameter Variant (%) Control (%) Variant mean±SD
Control 
mean±SD p value
Total number 86 108
Sex, male 59 (68.6) 83 (76.9) 0.198
Age of onset (years)a 25.24±9.96 25.05±9.50 0.883
   ≤16 7 (8.1) 8 (7.4)
   16< <40 74 (86.0) 92 (85.2) 0.896
   ≥40 5 (5.8) 8 (7.4)
Body mass index 19.90±3.00 20.04±3.11 0.760
Locationa
   Ileal (L1)±L4 24 (27.9) 18 (16.7)
   Colonic (L2)±L4 15 (17.4) 13 (12.0) 0.054
   Ileocolonic (L3)±L4 47 (54.7) 77 (71.3)
Perianal fistula 36 (41.9) 58 (53.7) 0.101
aAccording to the Montreal Classification [23]. 
L4 indicates upper gastrointestinal involvement.
SD, standard deviation.
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onset, body mass index, or disease location in Korean patients 
with CD (Table 3). Then, we examined the association between 
OCTN1 functional promoter haplotypes and clinical course of 
CD. We found that OCTN1 haplotypes significantly affected 
the time to development of a penetrating disease behavior (log-
rank p=0.008, Fig. 1), while other clinical events such as usage 
of azathioprine or anti-TNF agents or surgery were not affected 
by the haplotypes (data not shown). The risk of a penetrating 
behavior was significantly higher in patients in the variant group 
compared to the control group (hazards ratio (HR)=2.428, 
p=0.009) after adjustment for sex and age of onset in a Cox 
proportional hazards model (Table 4). The usage of azathioprine 
or anti-TNF agents and need for surgery were comparable 
between the two groups.  
DISCUSSION
Crohn’s disease (CD) is a chronic relapsing inflammatory 
disease and its incidence and prevalence are increasing with 
time [24]. Although the etiopathogenesis of CD is unclear, it is 
well accepted that this disease could be caused by dysregulated 
immune responses in genetically susceptible subjects [9]. 
Previous genome-wide or genotype-phenotype association 
studies have reported a significant association between genetic 
variants and susceptibility to or clinical phenotypes of CD [10-
13]. In particular, it was shown that several genetic variants 
of IL12B, TNFSF15, IL23R, and ATG16L2 were associated 
with susceptibility to or phenotypes of CD in Koreans [25-27]. 
The TC haplotype consisting of OCTN1, L503F and OCTN2, 
g.–207G>C was shown to be a predictor of CD development 
[4]. Several studies have found that L503F and –207G>C are 
ethnic-specific variants. For example, it has been reported that 
the frequencies of L503F and –207G>C were 0.412 and 0.500, 
respectively, in Europeans [7,28]. In those studies, the frequencies 
of these variants were also high in Mexicans: the frequencies 
of L503F and –207G>C were 0.230 and 0.679, respectively. 
However, interestingly, both are absent in Asian populations 
[17-19]. Recently, we reported that the functional haplotype of 
the OCTN2 promoter was associated with the clinical course in 
Korean CD patients [29]. In that study, compared to the controls, 
we observed much higher frequencies of a penetrating behavior 
and need for surgery in patients with the OCTN2 haplotype 
showing decreased promoter activity. 
In the present study, we evaluated the clinical usefulness 
of OCTN1 functional haplotypes identified in our previous 
study [8]. First, we investigated the association between genetic 
variants of the OCTN1 promoter and CD. The four variants 
showing significant changes in promoter activity in our previous 
study were not associated with susceptibility to CD in Koreans. 
In addition, the frequencies of all variants or haplotypes were 
comparable between patients and healthy controls. Vermeire 
et al. [30] previously reported that OCTN1, L503F was not 
associated with susceptibility to inflammatory bowel diseases, 
including CD, but was associated with the clinical phenotypes of 
Table 4. Clinical course of patients according to OCTN1 haplotypes 
Parameter Variant (%) Control (%) Hazards ratiob (95% CI) p value
Total number 86 108
Behaviora
   Inflammatory 40 (46.5) 68 (63.0)
   Stricturing 18 (20.9) 27 (25.0) 1.004c (0.549~1.837) 0.990
   Penetrating 28 (32.6) 13 (12.0) 2.428c (1.243~4.741) 0.009
Azathioprine or Anti-TNF agent use 64 (74.4) 81 (75.0) 0.795 (0.566~1.115) 0.184
Surgery 33 (38.4) 32 (29.6) 1.147 (0.702~1.875) 0.584
aAccording to the Montreal Classification. bAfter adjustment for other covariates (i.e., sex and age of onset). cHR of a multivariate Cox 
proportional hazards regression model with the inflammatory type as a reference category for the outcome variable.
CI, confidence interval. 
Fig. 1. Kaplan-meier curve for developing a penetrating disease 
behavior in Korean CD patients during follow-up. The log-rank test 
was performed between the OCTN1 variant (solid line) and control 
(dashed line) groups (p=0.008).
Association between OCTN1 haplotypes and CD
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the disease, particularly perianal or penetrating complications 
in the population that was studied. Therefore, we next examined 
whether OCTN1 functional promoter haplotypes could affect CD 
phenotypes. Previous studies reported that OCTN1 is expressed 
in the intestinal epithelium and plays a protective role against 
oxidative stress by transporting the anti-oxidant, ergothioneine 
[31,32]. Another study reported that the expression of OCTN2 
was increased in inf lamed areas in order to compensate for 
cellular damage [33]. Therefore, we hypothesized that patients 
with decreased OCTN1 activity by genetic variants would be 
susceptible to intestinal inflammation, and would demonstrate 
more severe CD phenotypes than patients with normal OCTN1 
activity. In our previous study, we determined that the OCTN1 
haplotypes that contain two variants, g.–1145A>G and g.–248C>G, 
showed reduced promoter activity [8]. Among the six OCTN1 
promoter haplotypes in the present study, five haplotypes (H2 
to H6) contained these variants. Therefore, we compared the 
characteristics or clinical course of patients according to these 
five haplotypes. We found that the frequency of a penetrating 
behavior was much higher in patients in the variant group. 
There are several limitations in the present study. First, the 
sample number of our study population was relatively small. In 
this study, we could not find any significant effect of OCTN1 
genotypes or haplotypes on susceptibility to CD. Validation with a 
larger number of patients of various ethnic groups is necessary to 
confirm these negative associations. Second, because the analysis 
of the genotype-phenotype of CD was performed retrospectively 
in the present study, we could not consider environmental factors 
in our analysis. However, we compared smoking history in some 
patients according to the OCTN1 functional haplotypes; there 
was no significant difference in the number of smokers (30.9% 
of 62 patients in the variant group vs. 39.4% of 71 patients in the 
control groups, p=0.290). 
In conclusion, we found that OCTN1 functional promoter 
haplotypes could affect the clinical phenotype of CD in Koreans, 
although the susceptibility to CD was unrelated to OCTN1 
genotypes or haplotypes. To our knowledge, this is the first study 
to examine the association between CD and genetic variants of 
the OCTN1 promoter. The presence of these haplotypes may be 
an important predisposing factor for developing a penetrating 
behavior in CD. 
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